You are here

Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study

Last updated on November 21, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Torino, , 10128 Italy
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Eighteen years of age or older with diagnosis of RA based on the 1987 American
College of Rheumatology (ACR) criteria and in accordance with local guidelines.

- Patients eligible to anti-TNF therapy

- Patients naïve to anti-TNFa drugs

- Patients with radiography (hands and feet) executed by 6 months before the baseline
or at baseline according to modified Sharp Van der Hejde method [Sharp JT et al.
1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of
understanding and completing the questionnaire Patients capable of understanding and
signing an informed consent form

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with tumors

- Patients already included in clinical trials

NCT00793403
Pfizer
Completed
Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Rheumatoid Arthritis
NCT03981900
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis, Psoriatic Arthritis
NCT02984020
All Genders
19+
Years
Multiple Sites
Descriptive Information
Brief TitleCurrent Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study
Official TitleCurrent Adoption Of Composite Indices In Evaluating Rheumatoid Arthritis Patients: An Observational Study ("NEW INDICES Study")
Brief SummaryThis is an observational study of composite indices, including the CLARA (CLinical ARthritis Activity) index, in rheumatoid arthritis (RA) patients in routine clinical practice in Italy in order to evaluate clinical remission and low disease activity. Data will be collected only from patients providing informed consent. In this study we aimed to assess the psychometric properties of a new composite instrument termed CLinical ARthritis Activity (PRO-CLARA) that uses only three PRO measures from among the 7 ACR Core Data Set. We hypothesized that this index would facilitate rapid and easy RA activity assessment in daily routine.
Detailed DescriptionAll patients who respond to inclusion/exclusion criteria at baseline will be considered valuable for the analysis.
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodProbability Sample
Study Populationprimary care clinic
ConditionRheumatoid Arthritis
InterventionOther: As per routinary clinical care
As per routine clinical care
Other Name: Observational study
Study Groups/Cohorts1
As per routine clinical care
Intervention: Other: As per routinary clinical care
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: December 31, 2012)
293
Original Estimated Enrollment
 (submitted: November 18, 2008)
400
Actual Study Completion DateJune 2010
Actual Primary Completion DateJune 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.
  • Patients eligible to anti-TNF therapy
  • Patients naïve to anti-TNFa drugs
  • Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form

Exclusion Criteria:

  • Patients with tumors
  • Patients already included in clinical trials
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesItaly
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00793403
Other Study ID Numbers0881A1-102317
0881A-102317 ; B1801118
Has Data Monitoring CommitteeYes
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateDecember 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now